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Summary
Objective: Characterize the effects of alendronate (ALN) on the repair process of the osteonecrotic femoral head as well as the development
of secondary osteoarthritis in the ipsilateral hip in an established experimental model of osteonecrosis.
Methods: Osteonecrosis of the femoral head was induced surgically in 60 adult, male New Zealand white rabbits. Animals were randomized in
two placebo- (saline) and two treatment-groups (ALN 150 mg/kg/day S.C., 3 per wk) and were euthanized at 6 and 12 months post-
operatively. Contralateral hip was used as control. Micro-Quantitative-CT (mQCT) analysis as well as histological assessment was
performed in the femoral head and the acetabulum. Mankin Score was used to assess cartilage degeneration in the acetabulum.
Results: Repair in the osteonecrotic femoral head in the placebo group led to a signiﬁcantly increased bone volume fraction (BVF) and
volumetric bone mineral density (vBMD) in the trabecular region and to an increase in porosity in the cortical and subchondral region
when compared to the normal femoral head on the contralateral side. ALN treatment signiﬁcantly further increased BVF and vBMD in the
trabecular region, and signiﬁcantly reduced porosity and increased vBMD in the necrotic subchondral and cortical bone when compared to
placebo. ALN led to a signiﬁcant increase in vBMD in the subchondral region of the osteoarthritic acetabulum as well as to a signiﬁcant
reduction in articular cartilage degeneration.
Conclusion: Inhibition of bone resorption by ALN treatment during repair of the osteonecrotic femoral head signiﬁcantly increased bone mass
in the trabecular region of the femoral head, inhibited subchondral resorption and reduced cartilage degeneration in the acetabulum.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteonecrosis of the femoral head is a common disease in
a relatively young patient population, with an average age
of 36 years1,2. If left untreated, the disease progresses
and can ultimately lead to the collapse of the femoral
head and hip joint destruction3,4. In the early stage of the
disease joint-preserving surgical techniques are often con-
sidered, which also have a signiﬁcant failure rate and mor-
bidity5,6,7,8. Total hip arthroplasty (THA) is often the
procedure of choice in the treatment of osteonecrosis of
the hip7. However, THA may be not an attractive option
for this young patient population. It is desirable to avoid or
at least delay THA, because most of these young patients
outlive the current state-of-the art prostheses and some
studies suggest less than satisfactory results of hip arthro-
plasty in this patient population6,9.*Address correspondence and reprint requests to: Dr Jochen G.
Hofstaetter, M.D., Department of Orthopaedics, Vienna General
Hospital, Medical University of Vienna, Waehringer Guertel 18-20,
A-1090 Vienna, Austria. Tel: 43-1-40400-4060; Fax: 43-1-40400-
4088; E-mail: jochen.hofstaetter@meduniwien.ac.at
Received 1 February 2008; revision accepted 29 July 2008.
362The pathogenesis that leads to the collapse of the femoral
head with subsequent hip joint destruction is not entirely
clear. The mechanical behavior of a structure depends on
the material and geometric properties of the structure10.
Bone cell death per se does not change the trabecular archi-
tecture, and may not on its own explain the structural failure
of the femoral head. Results from earlier studies11,12,13,14
suggested that the resorption of necrotic bone, especially
compact bone during the repair process may play a role in
the weakening of the structural properties of the femoral
head. If bone resorption associated with osteonecrosis can
be inhibited or delayed until sufﬁcient new bone has formed,
it would appear that structural failure could be delayed or
avoided. Bisphosphonates, synthetic analogues of pyro-
phosphate, have emerged as valuable drugs in the treatment
of osteoporosis and Padget’s disease15. ALN has been
shown to prevent resorption of necrotic bone during revascu-
larization without impairing new bone formation in a bone
chamber study in rats16. Recent studies have shown very
promising results with bisphosphonate treatment in experi-
mental Perthes disease17,18 as well as in traumatic osteo-
necrosis of the femoral head in adolescents19. Although
there are already data from clinical studies reporting
promising preliminary results using bisphosphonates in
the treatment of osteonecrosis of the femoral head in
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on the effects of bisphosphonates in the treatment of adult
osteonecrosis. Moreover, previously reported experiments
only evaluated the femoral head and did not address
secondary changes in the ipsilateral acetabulum17,18.
In recent years, micro-computed tomography (mCT) has
been shown to be a sensitive tool in characterizing three-
dimensional (3-D) bone microarchitecture and in various
conditions and explaining mechanisms of bone failure23.
mCT has been shown to be more sensitive to changes in
bone microstructure than conventional histomorphometry24
and has been used very successfully to characterize bony
changes in osteoarthritis25,26,27 as well as experimental
osteonecrosis14.
In this study we used Micro-Quantitative-CT (mQCT) and
histology to characterize the long term effects of ALN on the
repair process of the osteonecrotic femoral head as well as
the development of secondary osteoarthritis in the ipsilat-
eral acetabulum, in an established experimental model of
osteonecrosis in adult male rabbits14.Material and methodsANIMAL MODELSixty unselected 10e12 month old, male New Zealand white rabbits
were purchased from a USDA-licensed dealer (Millbrook ImmunoServ,
Inc., Amherst, MA, USA). Rabbits were housed in single cages in a 12/
12 h light/dark cycle and fed with standard Purina Chow in accordance
with the National Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals. The animal use protocol was approved by the Animal
Care and Use Committee at the Children’s Hospital Boston, MA. The animal
model was described earlier in detail14. In brief, the animals were premedi-
cated with 0.05 mg/kg glycopyrolate IM, 10 mg/kg ketamine IV and 0.5 mg/
kg acepromazine IV. General anesthesia was maintained with the use of
2e3% of isoﬂurane with oxygen via an endotracheal tube. Under aseptic
conditions, a posterior approach to the left hip was used. The hip joint
capsule was completely removed and the periosteum and blood vessels
covering the femoral neck were cauterized circumferentially to interrupt
the blood supply to the femoral head. The ligamentum teres was then
ligated with a nonresorbable suture (Ethibond Excel 5.0, Ethicon GmbH,
D-22851 Norderstedt, Germany). A 3-mm drill hole was made through the
posterior femoral neck into the marrow cavity, which was then cauterized
to interrupt the intramedullary blood supply to the femoral head. Prophylac-
tic antibiotics (25 mg/kg cefazolin IV) were given preoperatively and 2 h
post-operatively. The rabbits were allowed full weight-bearing post-
operatively. Post-operative pain was managed with IM injection of
0.03 mg/kg buprenorphine q 12 h buprenorphine twice daily for 3 days
post-operatively. The left hip in all of the animals was used for the produc-
tion of osteonecrosis, the right non-operated hip served as a control.TREATMENT GROUPSSixty rabbits were randomized into four groups of 15 animals each. Two
treatment-groups received ALN at a dose of 150 mg/kg/day (s.c., 3 per
wk) and two placebo groups received normal saline-injections (s.c., 3 per
wk) starting 1 month post-surgery. The dosage of ALN was recommended
by Gideon Rodan, Ph.D., Merck & Co., Inc. The dosage corresponds to
the oral dosage in humans for osteoporosis treatment. Due to the low oral
bioavailibility of bisphosphonates in human, the dosage the rabbits received
is estimated to be at least 50-fold higher. Rabbits of the placebo group and
the treatment group were sacriﬁced at 6 and 12 months post-surgery each
with an i.v. injection of Fatal Plus. The time-points 6 and 12 months were
chosen, based on our previous publication using the same animal model14,
in which we found very little signs of repair at 4 weeks after surgery, but
a marked repair response at 6 months.TISSUE HARVEST AND IMAGINGBilateral proximal femora and acetabuli from the placebo groups and the
osteonecrotic femoral head with the ipsilateral acetabulum from the ALN
groups were harvested and ﬁxed in 10% neutral buffered formalin (NBF)
for 7 days. Samples were then placed in a special polycarbonate specimen
tube ﬁlled with distilled water and scanned by a cone beam mQCT system
(GE Healthcare BioSciences). Data sets with isotropic 18 mm voxel spacingwere acquired at 0.5 steps over a total rotation of 360 at 80 kVp (plus
0.5 mm of Al and 15 mm of acrylic added ﬁltration). The specimen tube
was surrounded by an acrylic ﬁeld ﬂattener (21 mm thick) in order to mini-
mize beam hardening. A polycarbonate calibration phantom containing
2.3 mm diameter cylinders of air, water and SB3, a hydroxyapatite (HA) mim-
icking material, (Gammex RMI, Middleton, WI) was scanned in order to scale
values of CT attenuation to bone mineral density (BMD). A linear model con-
sisting of a two-point calibration was used to map individual voxel intensity
values to BMD. The mean attenuation of water represented 0 mg/cc of HA
while the mean attenuation within the SB3 calibrator represented a density
of 1030 mg/cc of HA. Using two-point calibration, attenuation values were
both interpolated and extrapolated to determine volumetric bone mineral
density (vBMD, mg mineral/cc).
Images were reconstructed into 3-D volumes using true Feldkamp re-
construction with 16-bit gray levels. Unbiased bone volume fraction
(BVF) in the trabecular region was calculated from the 3-D images using
MicroViewª software (GE Health Care). Thresholds for each specimen
were chosen to separate bone from marrow by determining the HU value
that maximized the between class variance of water and bone values in
the mCT scans28.
Measurements were taken in standardized positions in four different
regions (anterior, posterior, medial, lateral) in the cortical bone of the femoral
neck (cross-section) and in ﬁve regions in the subchondral bone of the fem-
oral head (sagital-section) and values were averaged. Anatomical landmarks
and length measures were used for orientation. At each position apparent
porosity (percentage of void volume in the cortex; porosity¼ 1 BVF) and
vBMD (mg mineral/cc) were determined. In the trabecular region of the fem-
oral head bone a 9 mm3 volume of interest (VOI) was positioned in the center
of the femoral head and microstructural parameters mentioned above as well
as vBMD were determined. Thickness, vBMD and apparent porosity were
determined in the subchondral bone of the central portion of the weight-
bearing region of the acetabulum. Femoral head sphericity was determined
using mCT images. A femoral head was considered collapsed when a clear
fracture line and/or femoral head deformation was present.HISTOLOGYAfter scanning, the specimens were decalciﬁed with 25% formic acid
containing 10% NBF, processed, embedded in parafﬁn, sectioned, and
stained with hematoxylin and eosin and Safranin-O. The anterior and supe-
rior regions of the acetabulum were analyzed for the degree of histological
change using the Mankin Score29 modiﬁed as previously published30. All
sections were graded by two observers (JGH, JY) blinded to the group,
and median scores were determined for statistical analysis. The capability
of the system has been demonstrated, and it has been found useful for
systematic assessment of articular cartilage, as the categories included
in the scoring system encompass highly relevant histological and histo-
chemical variables29,30.STATISTICAL ANALYSISData and graphs are presented as mean SD. Paired Student t test (two-
tailed) was used to evaluate signiﬁcance between placebo-operated and
placebo-non-operated samples. Unpaired Student t test (two-tailed) was
used to evaluate signiﬁcance between the placebo-operated and ALN-
operated samples. Fisher’s exact test was used to evaluate statistical signif-
icance between placebo-operated and ALN-operated samples with regard to
the collapse of the femoral head. All calculations were performed using
Graph Pad Prism 4 for Windows (GraphPad Software, San Diego, CA,
USA) and statistical signiﬁcance was set at the 95% conﬁdence limit.ResultsFEMORAL HEADSix months post-surgery, no collapse of the osteonecrotic
femoral head was seen in the placebo group (0/15) and in
the ALN group (0/15). At 12 months post-surgery 2 out of
15 (13.3%) osteonecrotic femoral heads were collapsed in
the placebo group, whereas no collapse was seen in the
ALN group (0/15). However, this difference was not statisti-
cally signiﬁcant. Representative mCT images of the femoral
head and neck regions at 12 months post-surgery as well
as of a collapsed femoral head are presented in Fig. 1.
No difference in femoral sphericity was seen in the non-
collapsed femoral heads (data not shown).
Fig. 1. Representative mCT images of the femoral head (top) and the neck (bottom) at 12 months post-surgery. (a) Placebo group e non-op-
erated femoral head, (b) placebo group e operated femoral head (arrow¼ area of bone resorption), (c) ALN group e operated femoral head
(arrowhead¼ appositional bone formationþ absence of bone formation), and (d) placebo group e collapsed operated, femoral head
(arrow¼ fracture line). Red square in aec indicates region seen on histological sections in Fig. 3.
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[Fig. 2(a and b)]
At 6-month post-surgery, no signiﬁcant changes in poros-
ity and vBMD were seen between the groups. At 12 months,
vBMD of the osteonecrotic femoral head in the placebo
group was signiﬁcantly decreased by 11.28% (P< 0.05)
and porosity was increased 3.86-fold (P< 0.0001) when
compared to their contralateral non-operated side. ALN
treatment led to a 2.33-fold reduction (P< 0.005) in porosity
and a 13.37% (P< 0.05) increase in vBMD when compared
to placebo in the operated femoral heads.
No signiﬁcant difference in vBMD and porosity was found
between the osteonecrotic femoral head of the placebo
group and the osteonecrotic femoral head of the ALN group
at 12 months.
Trabecular region of the femoral head [Fig. 2(c and d)]
At 6 months and 12 months post-surgery, the repair
process in the osteonecrotic femoral head in the placebo
group led to a signiﬁcantly increased BVF (15.05%,
P< 0.005 and 13.71%, P< 0.05, respectively) and a signif-
icantly increased vBMD (9.19%, P< 0.05 and 17.64%,
P< 0.005, respectively), when compared to its contralateralnon-operated side. Six months and 12 months ALN treat-
ment signiﬁcantly further increased BVF (15.5%, P< 0.05
and 31.16%, P< 0.05, respectively) and vBMD (20.99%,
P< 0.005 and 30.51%, P< 0.005, respectively) in the os-
teonecrotic femoral head when compared to placebo. ALN
treatment resulted in 32.91% (P< 0.0001) and 49.14%
(P< 0.0001) higher BVF and 32.11% (P< 0.0001) and
53.53% (P< 0.0001) higher vBMD in the osteonecrotic fem-
oral head when compared to the non-operated femoral
head of the placebo group at 6 and 12 months, respectively.
Histological observations revealed different stages of re-
pair process in the trabecular region of the osteonecrotic
femoral head. During the repair process of osteonecrosis
new appositional bone formation occurs on the surface of
dead trabecular bone, following invasion of ﬁbrovascular re-
pair tissue, which is later remodeled (Fig. 3). ALN treatment
does not appear to inhibit bone formation in the repair pro-
cess (Fig. 3).
Cortical region of the femoral neck [Fig. 2(e and f)]
At 6 and 12 months post-surgery, porosity was signiﬁ-
cantly increased (2.59-fold (P< 0.0001) and 3.41-fold
(P< 0.0001), respectively) and vBMD was signiﬁcantly de-
creased (30.35%, P< 0.05 and 39.7%, P< 0.005,
Fig. 2. mQCT analysis of the femoral head of rabbits. (P-NO: placebo group e non-operated femoral head; P-O: placebo group e operated
femoral head; and ALN-O: ALN group e operated femoral head) * indicates P< 0.05; ** indicates P< 0.005; and *** indicates P< 0.0001.
Fig. 3. Representative histological sections (areas are marked with red square in Fig. 1) showing that ALN treatment inhibits resorption of
necrotic bone without inhibiting new bone formation. (a) Placebo group e non-operated femoral head, (b) placebo group e operated femoral
head, and (c) ALN group e operated femoral head, (arrow marks appositional bone formation, * marks necrotic bone). Length of scale bar
is 120 mm.
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Fig. 4. Representative mCT images of the acetabulum (direct view e top row; lateral view e middle row; and 3-D reconstruction of chondral/
subchondral region) at 12 months post-surgery. (a) Placebo group e non-operated femoral head, (b) placebo group e operated femoral head,
and (c) ALN group e operated femoral head.
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of the placebo group when compared to their contralateral
control side. At 6 months and 12 months ALN treatment
led to a signiﬁcant reduction in porosity (50.78%,
P< 0.005 and 58.8%, P< 0.005, respectively) and a sig-
niﬁcant increase in vBMD (þ33.6%, P< 0.05 and þ46.5%,
P< 0.05, respectively) in the osteonecrotic femoral head
when compared to the placebo group. No statistically signif-
icant difference was found between the ALN treated osteo-
necrotic femoral neck and non-operated femoral heads of
the placebo group.ACETABULUMIn the placebo group, the acetabular subchondral bone of
the operated hip was signiﬁcantly thicker (9.3%, P< 0.05
and 17.33%, P< 0.001, respectively) with a signiﬁcantly
higher porosity (1.82-fold, P< 0.05 and 3.67-fold,
P< 0.0001) and a decreased vBMD (8.03%, P< 0.005
and 13.26%, P< 0.005) when compared to the contralat-
eral non-operated side at 6 and 12 months post-surgery.
Representative mCT images of the acetabulum at the 12-
month time-point are presented in Fig. 4. In the acetabulum
of the ALN-treated operated hip, the subchondral bone had
a signiﬁcantly higher vBMD (þ4.45%, P< 0.05) than the ac-
etabulum of the placebo treated operated hip at 6 months,
while no differences were found with regard to thickness
and porosity. However, the 12 months ALN treatment led
to a signiﬁcant 55.56% (P< 0.005) reduction in porosity
and a signiﬁcant 11.53% (P< 0.05) increase in vBMD in
the acetabulum of the operated hip when compared to theplacebo group. Subchondral bone of the ALN-treated oper-
ated hip was signiﬁcantly thicker (þ5.3%, P< 0.05) at 6
months and 10.67% (P< 0.05) thicker at 12 months than
that of the non-operated hip of the placebo group and had
a signiﬁcantly higher porosity (þ63.2%, P< 0.05) at 12
months. All mCT data are presented in Fig. 5.HISTOLOGICAL GRADING ARTICULAR CARTILAGE
ACETABULUMAt 6 months, histological grading using the Mankin
Score29 of the articular cartilage of the acetabulum of the
operated hip showed that the placebo group (7.5 2.6,
P< 0.0001) as well as the ALN group (5.8 2.1,
P< 0.0001) developed secondary osteoarthritis when com-
pared to the non-operated hip of the placebo group
(0.3 0.2). Although the operated hip of the placebo group
showed more degeneration than the ALN group, the differ-
ence was not signiﬁcant (P< 0.058) at 6 months. At 12
months, however, there was a signiﬁcantly higher degree
of degeneration in the operated hip of the placebo group
than in the ALN group (14.5 4.3 vs 9.7 3.6, P< 0.005)
(Fig. 4d). Representative histological sections at 12 months
post-surgery are presented in Fig. 6(aec).Discussion
In this study we investigated the effects of high-dose ALN
treatment on the repair of osteonecrotic femoral heads as
well as the development of secondary osteoarthritis of the
Fig. 5. mQCT analysis of subchondral bone of the acetabulum (an-
terior region) in rabbits. (P-NO: placebo group e non-operated ac-
etabulum; P-O: placebo group e operated acetabulum; and ALN-O:
ALN group e operated acetabulum) * indicates P< 0.05; ** indi-
cates P< 0.05; and *** indicates P< 0.0001.
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osteonecrosis in adult rabbits. In the placebo group we ob-
served a signiﬁcant increase in BVF and vBMD at 6 months
post-operatively during the normal repair process in the tra-
becular region of the osteonecrotic femoral head when
compared to the contralateral control side. This increase
in bone mass can be explained by appositional new bone
formation on the surface of the dead trabeculae during the
repair process, consistent with histological ﬁndings. Mor-
phological evaluations of the rabbit model of osteonecrosis
used in the present study has been described in the previ-
ous publication14. In brief, at 4 weeks after the surgical
induction of osteonecrosis of the femoral head, the infracted
femoral heads appeared yellowish and pale. Histological
observations revealed that all of the operated femoral
heads displayed extensive cell death in the marrow space
and empty lacunae in most areas of the trabecular bone,although the extent of osteonecrosis varied slightly among
the animals. Repair responses were not evident at this
time. Marked repair responses to the necrotic bone, such
as revascularization and new bone formation on the sur-
faces of necrotic trabecular bone, were observed at 6
months after surgery. Kenzora et al. also reported apposi-
tional bone formation on top of dead trabecular bone in
an experimental model of osteonecrosis in rabbits31. ALN
treatment led to a signiﬁcant further increase in BVF and
vBMD in the osteonecrotic trabecular region when com-
pared to placebo. Despite the fact that ALN treatment has
been shown to decrease bone activation frequency32, our
data indicate that ALN treatment did not impair new bone
formation, but inhibited resorption of necrotic bone. Astrand
et al. also showed in a bone chamber study in rats that ALN
inhibited the resorption of necrotic bone, but did not impair
bone healing16. Bisphosphonates have shown to have an
initial positive effect on new bone formation in cortical heal-
ing, but did prolong the remodeling process33. In contrast,
resorption predominated the repair of dead compact cortical
and subchondral in the placebo group, which led to a de-
crease in vBMD and an increase in apparent porosity. In
our previous study using this animal model14, we found
no signiﬁcant decrease in vBMD and no increase in appar-
ent porosity in the cortical bone of the femoral neck due to
resorption at 4 weeks post-operative. However, we also
found a signiﬁcant reduction in vBMD and a signiﬁcant in-
crease in apparent porosity in the cortical femoral neck at
6 months post-operatively. These ﬁndings are in accor-
dance with an earlier publication from Kenzora et al.31 Re-
sorption of dead compact bone during the repair process of
osteonecrosis may weaken the structural properties of the
femoral head and may be in part responsible for the col-
lapse seen in the late stages of osteonecrosis11,14,31,34.
ALN treatment signiﬁcantly reduced the increase in porosity
and reduced the decrease in vBMD in the compact bone. In
this study, 12 months post-operative 13.3% (2/15) of the
osteonecrotic femoral heads from the placebo group were
collapsed, whereas no collapse (0/15) was seen in the
ALN group, however, this result was not signiﬁcant. Femo-
ral head and neck geometry, the biomechanics of the hip
joint as well as body weight are very different in rabbits
when compared to humans, which may be critical with
regard to the risk of femoral head collapse3,31.
Recent studies by Kim et al.17 as well as Little et al.18
have shown very promising results with bisphosphonate
treatment in experimental Perthes disease. They have
shown that early treatment with ibandronate using a surgical
piglet model17 and Zoledronic acid using a surgical rat
model18 prevents femoral head deformity following experi-
mental osteonecrosis of the juvenile femoral head. They
found that repair process in the necrotic femoral heads,
such as revascularization of the necrotic marrow space
and proliferation of mesenchymal and ﬁbroblastic cells,
started as early as 2 weeks post-operation. Osteoclastic
bone resorption, and femoral head ﬂattening occurred as
early as 4e8 weeks post-surgery. They started treatment
at the time of surgery and animals were euthanized at 4
and 8 weeks17 and 6 weeks18 post-surgery. In contrast, re-
pair response was not evident at 4 weeks after surgery in
our rabbit model of osteonecrosis14, suggesting that repair
process occurs much slower in the rabbit model than the
piglet model. Therefore, we decided to start the bisphosph-
onate treatment at 4 weeks post-surgery, and not at the
time of surgery.
Surgical osteonecrosis in a growing animal apparently
produces a more rapid femoral head deformity than in adult
Fig. 6. Representative histological sections of the articular cartilage and subchondral region of the anterior acetabulum (Safranin-O staining) at
12 months post-surgery. (a) P-NO: placebo group e non-operated acetabulum, (b) P-O: placebo group e operated acetabulum, (c) ALN-O:
ALN group e operated acetabulum, and (d) histological grading of articular cartilage degeneration using the Mankin Score. Length of scale bar
is 120 mm. ** indicates P< 0.05 and *** indicates P< 0.0001.
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the osteonecrotic femoral head during the repair process in
this study as well as in our previous report14 at 6 months
post-surgery, which is in contrast to the decrease in bone
mass seen in the experimental Perthes model in pig-
lets17,35. These ﬁndings indicate that there is a difference
in the repair process of necrotic bone between the ages
of growth and adulthood.
Moreover, previous studies on experimental osteonecro-
sis only evaluated the femoral head and did not pay atten-
tion to the acetabulum. The degree of osteoarthritis in the
acetabulum is a major determinant of whether a joint-
preserving technique or total hip replacement is indicated.
We found a signiﬁcant increase in thickness, porosity and
a decrease in vBMD in the subchondral bone of the
osteoarthritic ipsilateral acetabulum. These changes in the
osteoarthritic subchondral bone are in line with previouslypublished changes in osteoarthritic subchondral bone25,36.
ALN treatment led to a signiﬁcant decrease in porosity
with a signiﬁcant increase in vBMD. Moreover, articular
cartilage degeneration of the ipsilateral acetabulum of our
operated animals was signiﬁcantly less in the ALN treated
group, when compared to the placebo group. However,
we are not able to conclude whether the effects seen are
secondary to the effects on the osteonecrotic femoral
head, or due to direct effects on the acetabulum, or both.
Resorption of subchondral bone may play a critical role in
the development of osteoarthritis37. Recent studies have
shown that bisphosphonate-mediated inhibition of bone
resorption with the subsequent decrease in bone turnover
and the increase in bone mineralization does have a beneﬁ-
cial effect in the treatment of osteoarthritis38,39. The ﬁnding
of the development of osteoarthritis in the ipsilateral acetab-
ulum prior to severe changes in femoral head sphericity
369Osteoarthritis and Cartilage Vol. 17, No. 3and/or collapse implies that other mechanisms than just
mechanical may be involved in the disease process of
osteoarthritis following osteonecrosis of the femoral head.
Earlier studies reported differences in the synovial ﬂuid
composition between primary osteoarthritis and secondary
osteoarthritis following osteonecrosis, which could differen-
tially affect cartilage metabolism in the acetabulum40,41.
Our surgical model of adult osteonecrosis represents
traumatic osteonecrosis.Most experimentalmodels of osteo-
necrosis are burdened by the fact that interventions are
conducted in healthy animals. The etiology of osteonecrosis
is very diverse, such as alcohol use, high-dose corticoid ad-
ministration, coagulation abnormalities as well as genetic
polymorphism which may predispose certain patient cohorts
to the development of osteonecrosis3. These underlying dis-
easesmay affect bone repair andmay also affect the efﬁcacy
of pharmacological agents in the treatment of osteonecrosis.
High-dose bisphosphonate treatment was recently linked to
the development of maxillary osteonecrosis after dental pro-
cedures in tumor patients42,43. It is very likely that in patients
with severe diseases suchas cancer, the combination of che-
motherapywith high-dose bisphosphonate treatmentmay be
responsible for that ﬁnding.
Further experimental studies investigating the efﬁcacy of
bisphosphonates in various animal models of osteonecrosis
are needed in the future. Moreover, it needs to be investi-
gated if there are stage-speciﬁc differences in the efﬁcacy
of bisphosphonate treatment. Our results are very promis-
ing, that bisphosphonates may become an important part
in the treatment of osteonecrosis. However, we ought to
be very careful in selecting patients for bisphosphonate
treatment in osteonecrosis and we have to speciﬁcally
pay attention for side effects in the mandibular and maxillary
regions. Moreover it would be ideal not only to decrease re-
sorption but also to increase new bone formation during the
repair of the osteonecrotic femoral head11. Recent studies
using cell-based therapies44, gene-therapy45, and also the
addition of growth factors46e48 have yielded very promising
results for the future treatment of osteonecrosis. Future
studies are needed to explore the efﬁcacy of combining
several treatment modalities such as antiresorptive drugs,
an osteogenic stimulus, and joint-preserving surgery for
the treatment of early stage osteonecrosis of the femoral
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